Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 [Yahoo! Finance]